{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:40:10Z","timestamp":1791949210255,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd004094","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2003,10,20]],"date-time":"2003-10-20T00:00:00Z","timestamp":1066608000000}}],"reference-count":131,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004094.pub2","type":"journal-article","created":{"date-parts":[[2004,7,21]],"date-time":"2004-07-21T03:08:53Z","timestamp":1090379333000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Long-term pharmacotherapy for obesity and overweight"],"prefix":"10.1002","volume":"2010","author":[{"given":"Raj S","family":"Padwal","sequence":"first","affiliation":[{"name":"University of Alberta Hospital; 2E3.22 WMHSC; Edmonton, AB Canada T6G 2B7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rucker","sequence":"additional","affiliation":[{"name":"University of Alberta; Internal Medicine ; 8440-112 St Edmonton, AB Alberta Canada T6G 2B7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K","family":"Li","sequence":"additional","affiliation":[{"name":"University of Alberta ; Internal Medicine (PGY4); 10820-85 Ave Edmonton, AB Canada T6E 2L1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia","family":"Curioni","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro; Instituto de Medicina Social; Rua S\u00e3o Francisco Xavier, 524 \/ 7\u00ba andar \/ bloco D - Maracan\u00e3 Rio de Janeiro Brazil 20559-900"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David CW","family":"Lau","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Medicine; 2501-3330 Hospital Drive NW Calgary Alberta Canada T2N 4N1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,20]]},"reference":[{"key":"10.1002\/14651858.CD004094.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/00004872-200211000-00026","article-title":"Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension","volume":"20","author":"Bakris","year":"2002","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1464-5491.2004.01474.x","article-title":"A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin","volume":"22","author":"Berne","year":"2005","journal-title":"Diabet Med"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1742-1241.2002.tb11307.x","article-title":"Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study","volume":"56","author":"Broom","year":"2002","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat","volume":"281","author":"Davidson","year":"1999","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0149-2918(03)80070-X","article-title":"Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet","volume":"25","author":"Derosa","year":"2003","journal-title":"Clin Ther"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2004-817934","article-title":"Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT study","volume":"112","author":"Hauner","year":"2004","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","article-title":"Orlistat in the long-term treatment of obesity in primary care settings","volume":"9","author":"Hauptman","year":"2000","journal-title":"Archives of Family Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.ijo.0802591","article-title":"Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes","volume":"28","author":"Kaukua","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.ijo.0802281","article-title":"Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity","volume":"27","author":"Krempf","year":"2003","journal-title":"Int J Obese Relat Met Disord"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study","volume":"248","author":"Lindgarde","year":"2000","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.ejcn.1602172","article-title":"Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study","volume":"59(Suppl 1)","author":"Mathus-Vliegen EM for the Balance Study Group","year":"2005","journal-title":"European Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension","volume":"160","author":"McMahon","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.jhh.1001298","article-title":"Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled by angiotensin converting enzyme inhibitors","volume":"16","author":"McMahon","year":"2002","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity","volume":"8","author":"Rossner","year":"2000","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.clinthera.2004.09.017","article-title":"Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Sanchez-Reyes","year":"2004","journal-title":"Clin Ther"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0028|cit28","first-page":"505","article-title":"Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity","volume":"50","author":"Smith","year":"2001","journal-title":"Journal of Family Practice"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1463-1326.2004.00467.x","article-title":"Effect of orlistat on cardiovascular disease risk in obese adults","volume":"7","author":"Swinburn","year":"2005","journal-title":"Diab Obes Metab"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"Xenical in the prevention of diabetes in obese subjects (XENDOS) study","volume":"1","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0011-393X(02)80066-2","article-title":"Effects of orlistat, simvastatin, and orlistat plus simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial","volume":"63","author":"Derosa","year":"2002","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.jhh.1001877","article-title":"Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-labl, observational study","volume":"19","author":"Gaciong","year":"2005","journal-title":"Journal of Hum Hypertens"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0033|cit33","first-page":"21","article-title":"A prospective controlled trial of outpatients treatment for obesity","volume":"37","author":"Gilbert","year":"1983","journal-title":"Human Nutrition. Clinical Nutrition"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1463-1326.2002.00237.x","article-title":"The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.","volume":"4","author":"Hanefeld","year":"2002","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","article-title":"Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults","volume":"160","author":"Heymsfield","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","article-title":"Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study","volume":"69","author":"Hill","year":"1999","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diabres.2004.05.012","article-title":"Orlistat for obesity: benefits beyond weight loss","volume":"67","author":"Hsieh","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004094.pub2-BIB0038|cit38","first-page":"S24","article-title":"A one-year trial to assess the value of orlistat in the management of obesity","volume":"21","author":"James","year":"1997","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0002-9149(03)00112-7","article-title":"Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia","volume":"91","author":"Lucas","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.ijo.0802439","article-title":"Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification","volume":"27","author":"Poston","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2337\/diacare.22.6.896","article-title":"Pharmacologic induction of weight loss to treat type 2 diabetes","volume":"22","author":"Redmon","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2337\/diacare.26.9.2505","article-title":"One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial.","volume":"26","author":"Redmon","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2337\/diacare.28.6.1311","article-title":"Two-year outcome of a combination of weight loss therapies for type 2 diabetes","volume":"28","author":"Redmon","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0044|cit44","first-page":"1802","article-title":"Sibutramine - antidepressive agent tested against obesity","volume":"98","author":"Rossner","year":"2001","journal-title":"Ladartidningen"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1055\/s-2002-22671","article-title":"Treating obesity with sibutramine under practical conditions","volume":"127","author":"Scholze","year":"2002","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0046|cit46","first-page":"2395","article-title":"The effect of sibutramine for the maintenance of weight loss: a randomised, clinical, controlled study","volume":"163","author":"Toubro","year":"2001","journal-title":"Ugeskrift for Laeger"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archinte.161.2.218","article-title":"Benefits of lifestyle modification in the pharmacologic treatment of obesity","volume":"161","author":"Wadden","year":"2001","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1992.68","article-title":"Long-term weight control: The national heart, lung, and blood institute funded multimodal intervention study","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight loss with sibutramine","volume":"286","author":"Wirth","year":"2001","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1463-1326.2004.00428.x","article-title":"Reduction of body weight and co-morbidities by orlistat: the XXL - Primary Health Care Trial","volume":"7","author":"Wirth","year":"2005","journal-title":"Diab Obes Metab"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00004872-199816121-00024","article-title":"Treatment with orlistat reduces cardiovascular risk in obese patients","volume":"16","author":"Zavoral","year":"1998","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0053|cit53","unstructured":"ClinicalTrials.gov. Atherosclerosis underlying development assessed by intima-media thickness in patients on rimonabant (AUDITOR) http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00228176?order=1. Accessed March 2007. December 2005"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0054|cit54","unstructured":"ClinicalTrials.gov CRESCENDO: comprehensive rimonabant evaluation study of cardiovascular endpoints and outcomes http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00263042?order=3 (accessed March 2007) December 2005"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"L44","DOI":"10.1093\/eurheartj\/sui086","article-title":"The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients","volume":"7(suppl L)","author":"James","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0056|cit56","unstructured":"ClinicalTrials.gov. STRADIVARIUS (Strategy to reduce atherosclerosis development involving administration of rimonabant - the intravascular ultrasound study) http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00124332?order=1. Accessed March 2007 December 2005"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/sj.ijo.0800875","article-title":"Weight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies","volume":"23","author":"Allison","year":"1999","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00022","article-title":"Long-term effects of change in body weight on all-cause mortality","volume":"119","author":"Andres","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archinte.164.9.994","article-title":"The efficacy and safety of sibutramine for weight loss: a systematic review","volume":"164","author":"Arterburn","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0061|cit61","first-page":"483","article-title":"The cost of obesity in Canada","volume":"160","author":"Birmingham","year":"1999","journal-title":"Canadian Medical Association Journal"},{"issue":"Supp 2","key":"10.1002\/14651858.CD004094.pub2-BIB0062|cit62","first-page":"2112S","article-title":"Effect of degree of weight loss on health benefits","volume":"3","author":"Blackburn","year":"1995","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(98)22029-0","article-title":"Obesity: a time bomb to be defused","volume":"352","author":"Bray","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/35007544","article-title":"Medicinal strategies in the treatment of obesity","volume":"404","author":"Bray","year":"2000","journal-title":"Nature"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1056\/NEJM199910073411501","article-title":"Body-mass index and mortality in a prospective cohort of U.S. adults","volume":"341","author":"Calle","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educational and Psychological Measurement"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-122-7-199504010-00001","article-title":"Weight gain as a risk factor for clinical diabetes mellitus in women","volume":"122","author":"Colditz","year":"1995","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/14651858.CD004094.pub2-BIB0071|cit71","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006162.pub2","article-title":"Rimonabant for overweight or obesity","author":"Curioni","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","author":"The DREAM Trial Investigators","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1001\/archinte.161.13.1581","article-title":"Impact of overweight on the risk of developing common chronic diseases during a 10-year period","volume":"161","author":"Field","year":"2001","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.288.14.1723","article-title":"Prevalence and trends in obesity among US adults, 1999-2000","volume":"288","author":"Flegal","year":"2002","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/oxfordjournals.aje.a009844","article-title":"Prospective study of intentionality of weight loss and mortality in older women: the Iowa Women's Health Study","volume":"149","author":"French","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0078|cit78","first-page":"397","article-title":"Beneficial effects of modest weight loss","volume":"16","author":"Goldstein","year":"1992","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0889-8529(05)70367-4","article-title":"Obesity surgery","volume":"25","author":"Greenway","year":"1996","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","article-title":"Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials","volume":"26","author":"Haddock","year":"2002","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(05)67483-1","article-title":"Obesity","volume":"366","author":"Haslam","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0082|cit82","unstructured":"Health Canada Health Canada investigates safety of MERIDIA\u00ae (Sibutramine) http:\/\/www.hc-sc.gc.ca\/english\/protection\/warnings\/2002\/2002_21e.htm"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/S0140-6736(05)67663-5","article-title":"Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case control study","volume":"366","author":"Yusuf","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0085|cit85","unstructured":"International Obesity Task Force Global obesity map Available at http:\/\/www.iotf.org\/database\/documents\/GlobalAdultmapswithtop5ineachregion_000.ppt. Accessed January 2007"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199809103391102","article-title":"A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation","volume":"339","author":"Jick","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/9780470693926.ch5","article-title":"Assessing the quality of randomised controlled trials","volume-title":"Systematic Reviews in Health Care","author":"Juni","year":"2001"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM199809103391101","article-title":"The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs","volume":"339","author":"Khan","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1152\/physrev.1994.74.4.761","article-title":"Regional adiposity and morbidity","volume":"74","author":"Kissbah","year":"1994","journal-title":"Physiological Reviews"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/35007508","article-title":"Obesity as a medical problem","volume":"404","author":"Kopelman","year":"2000","journal-title":"Nature"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1503\/cmaj.070306","article-title":"Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children","volume":"176","author":"Lau","year":"2007","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1503\/cmaj.061409","article-title":"2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]","volume":"176","author":"Lau","year":"2007","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S1-130. Availab","DOI":"10.1503\/cmaj.070306","article-title":"2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children","volume":"176","author":"Lau","year":"2007","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199503093321001","article-title":"Changes in energy expenditure resulting from altered body weight","volume":"332","author":"Leibel","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0197-2456(03)00064-3","article-title":"Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes","volume":"24","author":"The Look AHEAD Research Group","year":"2003","journal-title":"Control Clin Trials"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1345\/aph.18319","article-title":"Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity","volume":"33","author":"Luque","year":"1999","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199509143331101","article-title":"Body weight and mortality among women","volume":"333","author":"Manson","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2165\/00003495-199856020-00007","article-title":"Orlistat","volume":"52","author":"McNeely","year":"1998","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reporting of meta-analysis of randomized controlled trials: the QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00026","article-title":"Methods for voluntary weight loss and control","volume":"119","author":"NIH Technology Assessment Conference Panel","year":"1993","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004094.pub2-BIB0104|cit104","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004095.pub2","article-title":"Pharmacotherapy for weight loss in adults with type 2 diabetes","author":"Norris","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/j.1550-8528.1994.tb00108.x","article-title":"Towards prevention of obesity: research directions","volume":"2","author":"The National Task Force on Prevention and Treatment of Obesity","year":"1994","journal-title":"Obes Res"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"O'Meara S Riemsma R Shirran L Mather L ter Riet G A rapid and systematic review of the clinical effectiveness and cost effectiveness of orlistat in the management of obesity Health Technology Assessment 2001","DOI":"10.3310\/hta5180"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0107|cit107","doi-asserted-by":"crossref","unstructured":"O'Meara S Riemsma R Shirran L Mather L ter Riet G The clinical effectiveness and cost effectiveness of sibutramine in the management of obesity: a technology assessment Health Technology Assessment 2002","DOI":"10.3310\/hta6060"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.288.14.1728","article-title":"Prevalence and trends in overweight among US children and adolescents, 1999-2000","volume":"288","author":"Ogden","year":"2002","journal-title":"Journal of the American Medical Association"},{"issue":"4","key":"10.1002\/14651858.CD004094.pub2-BIB0109|cit109","article-title":"Long-term pharmacotherapy for obesity and overweight","author":"Padwal","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2337\/diacare.28.3.736","article-title":"A systematic review of drug therapy to delay or prevent type 2 diabetes","volume":"28","author":"Padwal","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","article-title":"Drug treatments for obesity: orlistat, sibutramine and rimonabant","volume":"369","author":"Padwal","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0112|cit112","first-page":"In press","article-title":"Long-term persistence with orlistat and sibutramine in a population-based cohort","author":"Padwal","year":"2007","journal-title":"Int J Obes (Lond)"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0113|cit113","first-page":"221","article-title":"Antiobesity drug therapy: A call for more rigorous endpoint evaluation","volume":"4","author":"Padwal","year":"2007","journal-title":"Future Drugs"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/jama.1997.03540430051032","article-title":"A prospective study of body mass index, weight change, and risk of stroke in women","volume":"277","author":"Rexrode","year":"1997","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/oxfordjournals.aje.a117385","article-title":"Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men","volume":"141","author":"Rimm","year":"1995","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0116|cit116","first-page":"S13","article-title":"The impact of obesity on health status: some implications for health care costs","volume":"19(Suppl 6)","author":"Seidell","year":"1996","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMoa035622","article-title":"Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery","volume":"351","author":"Sjostrom","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0118|cit118","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch11","article-title":"Investigating and dealing with publication and other biases","volume-title":"Systematic Reviews in Health Care","author":"Sterne","year":"2001"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199801013380101","article-title":"The effect of age on the association between body-mass index and mortality","volume":"338","author":"Stevens","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Toumilehto","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1001\/archinte.158.17.1855","article-title":"Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults","volume":"158","author":"Expert Panel on the","year":"1998","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0122|cit122","unstructured":"Bray GA Health hazards associated with obesity UpToDate Clinical Reference Library [CD-ROM] 2001"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/sj.ijo.0801787","article-title":"A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study","volume":"25","author":"Visscher","year":"2001","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00012","article-title":"Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials","volume":"119","author":"Wadden","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199809103391103","article-title":"An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo","volume":"339","author":"Weissman","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0127|cit127","unstructured":"World Health Organisation (WHO) Obesity: Preventing and managing the Global Epidemic - Report of a WHO Consultation on Obesity, 3-5 June 1997 WHO\/NUT\/NCD\/98.1 1998"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"731","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00021","article-title":"The association between weight loss and increased longevity. A review of the evidence","volume":"119","author":"Williamson","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/oxfordjournals.aje.a117386","article-title":"Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years","volume":"141","author":"Williamson","year":"1995","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0130|cit130","first-page":"1499","article-title":"Type 2 diabetic subjects lose less weight than their overweight spouses.","volume":"23","author":"Wing","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004094.pub2-BIB0131|cit131","first-page":"1307","article-title":"Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias","volume":"166","author":"Wooltorton","year":"2002","journal-title":"Canadian Medical Association Journal"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004094.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:04:08Z","timestamp":1783904648000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004094.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2003,10,20]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004094.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,20]]}}}